Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

BACKGROUND: Insulin resistance with elevated glucose is a risk factor for non-alcoholic steatohepatitis (NASH). We investigated the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor luseogliflozin on NASH development using a rodent model. METHODS: Mice were treated with both nicotinami...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetol Metab Syndr
Hlavní autoři: Qiang, Shirong, Nakatsu, Yusuke, Seno, Yasuyuki, Fujishiro, Midori, Sakoda, Hideyuki, Kushiyama, Akifumi, Mori, Keiichi, Matsunaga, Yasuka, Yamamotoya, Takeshi, Kamata, Hideaki, Asano, Tomoichiro
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2015
Témata:
Short Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4653899/
https://ncbi.nlm.nih.gov/pubmed/26594248
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13098-015-0102-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky